)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lipella Pharmaceuticals
Lipella Pharmaceuticals (LIPO) investor relations material
Lipella Pharmaceuticals has been otc
Lipella Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Focused on developing reformulated generic drugs for new indications, with lead programs LP-10 (hemorrhagic cystitis) and LP-310 (oral lichen planus) in clinical development; LP-410 (oral GVHD) and LP-50 (bladder cancer) in earlier stages.
No commercialized products; revenue derived from NIH grants, which expired in June 2025.
Announced completion of LP-310 Phase 2a trial in Q3 2025, with positive safety and tolerability data.
Chief Medical Officer announced retirement effective December 2025.
Financial highlights
Revenue for Q3 2025 was $0, down from $80,380 in Q3 2024 due to grant expiration.
Net loss for Q3 2025 was $1.25M, improved from $1.44M in Q3 2024; net loss for nine months ended September 30, 2025 was $3.89M, up from $3.57M in 2024.
R&D expenses for Q3 2025 were $721K, down $326K year-over-year, mainly due to lower stock option expense.
General and administrative expenses for Q3 2025 were $552K, up $60K year-over-year, driven by higher professional and outside services.
Cash and cash equivalents at September 30, 2025 were $1.86M.
Outlook and guidance
Existing cash expected to fund operations through the end of 2025, but additional capital will be required for continued development.
Anticipates continued operating losses and negative cash flows due to ongoing R&D and clinical activities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lipella Pharmaceuticals
- Biotech registers 1.37M shares for resale, targeting rare diseases and facing Nasdaq risks.LIPO
Registration Filing - Biotech registers 5.6M shares for resale, supporting pipeline and working capital amid Nasdaq risks.LIPORegistration Filing
- Annual meeting to vote on director elections, reverse stock split, and auditor ratification.LIPOProxy Filing
- Shareholders will vote on issuing 20%+ of stock via an equity line to regain Nasdaq compliance.LIPOProxy Filing
- Annual meeting to vote on directors, stock plan amendment, share issuances, and auditor ratification.LIPOProxy Filing
- Shareholders will vote on director elections, a reverse stock split, and auditor ratification.LIPOProxy Filing
- Shareholders to vote on issuing 20%+ new shares via ELOC to regain Nasdaq compliance and fund growth.LIPOProxy Filing
- Special stockholder meeting adjourned for lack of quorum, rescheduled for December 27, 2024.LIPOProxy Filing
- Special stockholder meeting adjourned for lack of quorum, rescheduled for December 20, 2024.LIPOProxy Filing
Lipella Pharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lipella Pharmaceuticals Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for urologic and other rare diseases. The company specializes in the reformulation and delivery of existing drugs using proprietary technology to treat conditions such as interstitial cystitis, hemorrhagic cystitis, and other bladder-related disorders. Lipella conducts research and clinical trials to advance its drug candidates through regulatory pathways. The company is headquartered in Pittsburgh, Pennsylvania, and its shares are listed on the CSE.